Literature DB >> 29131151

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.

S Pagliuca1, A M Risitano2, F S De Fontbrune1, M Robin1, A P Iori3, S Marotta2, D Michonneau1, A Villate4, D Desmier5, G Socié1, R P De Latour1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29131151     DOI： 10.1038/bmt.2017.220

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

1.  Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience.

Authors:  Morag Griffin; Austin Kulasekararaj; Sheyans Gandhi; Talha Munir; Stephen Richards; Louise Arnold; Nana Benson-Quarm; Nicola Copeland; Isabel Duggins; Kathryn Riley; Peter Hillmen; Judith Marsh; Anita Hill
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

Review 2.  Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.

Authors:  Antonio M Risitano; Serena Marotta; Patrizia Ricci; Luana Marano; Camilla Frieri; Fabiana Cacace; Michela Sica; Austin Kulasekararaj; Rodrigo T Calado; Phillip Scheinberg; Rosario Notaro; Regis Peffault de Latour
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 3.  Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow.

Authors:  Antonio G Solimando; Carmen Palumbo; Mary Victoria Pragnell; Max Bittrich; Antonella Argentiero; Markus Krebs
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.